Trials / Unknown
UnknownNCT03132025
Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer
Phase 1 Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Yanqiao Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To control apatinib and capecitabine combination to maintain treating metastatic colorectal cancer.
Detailed description
To control apatinib and capecitabine combination to maintain treating metastatic colorectal cancer,primary endpoint include in mPFS; secondary endpoint include in mOS, tolerance and security.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | "Apatinib" and "Capecitabine" | Combine "Apatinib" and "Capecitabine" to Maintain Treating Metastatic Colorectal Cancer |
| DRUG | "Capecitabine" | Single Drug "Capecitabine" to Maintain Treating Metastatic Colorectal Cancer |
Timeline
- Start date
- 2017-04-30
- Primary completion
- 2018-02-28
- Completion
- 2018-04-30
- First posted
- 2017-04-27
- Last updated
- 2017-04-27
Source: ClinicalTrials.gov record NCT03132025. Inclusion in this directory is not an endorsement.